Related Experiment Video
Updated: Aug 23, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Synergistic killing of human leukemia cells by antioxidants and trichostatin A
Jiuhong Kang1, Jie Chen, Dawei Zhang
1School of Life Sciences, Lanzhou University, Lanzhou, China. kangjiuhong@lzu.edu.cn
Purpose:
Antioxidants and trichostatin A (TSA) are promising anticancer drugs, and are capable of enhancing the neoplastic toxicity of other chemicals that exert anticancer activity via different mechanisms. Since antioxidants and TSA (the specific inhibitor of histone deacetylase) are believed to combat cancer via different mechanisms, we sought to determine whether combining them would improve their anticancer activity in human leukemia cells (HL-60).
Materials And Methods:
HL-60 cells were treated with antioxidants (ascorbic acid, AA and N-acetyl-cysteine, NAC), TSA or their combination, and cell proliferation arrest, lactate dehydrogenase (LDH) release and cell viability were measured as indicators of cell damage. Accumulation of reactive oxygen species (ROS) and the acetylation of histones were also measured.
Results:
The cytotoxicity of AA, NAC and TSA increased in a time- and dose-dependent manner. AA (1, 2 and 4 mM) and NAC (0.2, 0.5 and 1 mM) were able to diminish ROS generation but showed no influence on histone acetylation in HL-60 cells. In contrast, TSA (20, 50, 100 and 200 nM) did not inhibit ROS generation but significantly increased histone acetylation, indicating a possible role for both scavenging ROS and increasing histone acetylation in the induction of cell death in HL-60 cells. This conclusion was further confirmed by the finding that the combination of antioxidant and TSA not only diminished ROS generation, but also increased histone acetylation, and hence showed greater cytotoxicity in HL-60 cells than either component alone.
Conclusions:
Our findings show that combining antioxidants and TSA can enhance their neoplastic toxicity at least in human leukemia HL-60 cells, providing a new approach to the design of chemotherapy strategies and the development of anticancer drugs.
Insights
Combining antioxidants like ascorbic acid (AA) and N-acetyl-cysteine (NAC) with trichostatin A (TSA) enhances anticancer effects in human leukemia cells. This combination therapy shows greater efficacy than individual treatments by targeting both reactive oxygen species and histone acetylation.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Antioxidants and trichostatin A (TSA) are recognized for their individual anticancer properties.
- These agents are thought to combat cancer through distinct mechanisms.
- Investigating synergistic effects is crucial for developing novel chemotherapy strategies.
Purpose of the Study:
- To evaluate the combined anticancer efficacy of antioxidants (ascorbic acid, AA; N-acetyl-cysteine, NAC) and TSA in human leukemia (HL-60) cells.
- To determine if combining these agents enhances neoplastic toxicity compared to monotherapy.
- To explore the underlying mechanisms of action for the combination therapy.
Main Methods:
- HL-60 cells were treated with varying doses of AA, NAC, TSA, or their combinations.
- Cell proliferation arrest, lactate dehydrogenase (LDH) release, and cell viability were assessed.
- Reactive oxygen species (ROS) accumulation and histone acetylation levels were measured.
Main Results:
- Both antioxidants (AA, NAC) and TSA demonstrated dose- and time-dependent cytotoxicity.
- Antioxidants reduced ROS generation but did not affect histone acetylation.
- TSA increased histone acetylation without affecting ROS generation.
- The combination therapy significantly enhanced cytotoxicity, reduced ROS, and increased histone acetylation.
Conclusions:
- Combining antioxidants with TSA amplifies their anticancer effects in HL-60 leukemia cells.
- This synergistic approach offers a promising strategy for developing novel anticancer drugs.
- Targeting both ROS and histone acetylation represents a potential dual-action chemotherapy mechanism.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Antiprotozoal Agents
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...